MA29622B1 - Compositions permettant de reduire l'incidence d'une arythmie d'origine medicamenteuse - Google Patents

Compositions permettant de reduire l'incidence d'une arythmie d'origine medicamenteuse

Info

Publication number
MA29622B1
MA29622B1 MA30561A MA30561A MA29622B1 MA 29622 B1 MA29622 B1 MA 29622B1 MA 30561 A MA30561 A MA 30561A MA 30561 A MA30561 A MA 30561A MA 29622 B1 MA29622 B1 MA 29622B1
Authority
MA
Morocco
Prior art keywords
compositions
drug
incidence
methods
reducing
Prior art date
Application number
MA30561A
Other languages
English (en)
Inventor
Joseph Michael Ii Sprafka
Jose Mauro Goulart-Brum
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of MA29622B1 publication Critical patent/MA29622B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne de nouveaux procédés et de nouvelles préparations permettant de traiter et de prévenir l'incidence d'une proarythmie d'origine médicamenteuse, y compris des torsades de pointes. Les procédés et les préparations comprennent une combinaison d'un médicament qui induit des torsades de pointes, tel que des anti-arythmisants de classe HI, certains agents antimicrobiens, des antihistaminiques, des antidépresseurs, des antipsychotiques, des diurétiques, avec de l'aspirine et/ou une statine. Dans certains modes de réalisation, les compositions et les procédés de traitement comprennent de l'azimilide et de l'aspirine et/ou une statine. Ces compositions peuvent être administrées par différentes voies, notamment par voie orale. Dans certains modes de réalisation dans lesquels l'anti-arythmisant est de l'azimilide, celui-ci peut être administré par voie orale à une dose allant d'environ 25 mg à environ 300 mg.
MA30561A 2005-07-22 2008-01-09 Compositions permettant de reduire l'incidence d'une arythmie d'origine medicamenteuse MA29622B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US70155505P 2005-07-22 2005-07-22

Publications (1)

Publication Number Publication Date
MA29622B1 true MA29622B1 (fr) 2008-07-01

Family

ID=37547445

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30561A MA29622B1 (fr) 2005-07-22 2008-01-09 Compositions permettant de reduire l'incidence d'une arythmie d'origine medicamenteuse

Country Status (19)

Country Link
US (2) US8183284B2 (fr)
EP (1) EP1906966A2 (fr)
JP (1) JP4880685B2 (fr)
KR (1) KR20080017489A (fr)
CN (1) CN101227908A (fr)
AR (1) AR055091A1 (fr)
AU (1) AU2006271230A1 (fr)
BR (1) BRPI0613670A2 (fr)
CA (1) CA2615975C (fr)
IL (1) IL188831A0 (fr)
MA (1) MA29622B1 (fr)
MX (1) MX2008001063A (fr)
NO (1) NO20080890L (fr)
PE (1) PE20070369A1 (fr)
RU (1) RU2376994C2 (fr)
SM (1) SMP200800012B (fr)
TW (1) TW200744613A (fr)
WO (1) WO2007010498A2 (fr)
ZA (1) ZA200800564B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105534976A (zh) * 2016-01-14 2016-05-04 山东大学 2-(2,2-二苯基环丙基)-4,5-二氢-1h-咪唑在制备抗神经退化性疾病药物中的应用
JP7042256B2 (ja) * 2016-05-19 2022-03-25 タブラ・ラサ・ヘルスケア，インコーポレーテッド 薬剤関連毒性が低減した治療法および処方薬に起因する患者危害の可能性を確認する方法
JPWO2018124236A1 (ja) * 2016-12-27 2019-11-14 国立大学法人大阪大学 難治性心疾患治療用医薬組成物
JP2022506440A (ja) 2018-11-02 2022-01-17 セルトリオン， インク． 肥大型心筋症治療用薬学組成物
CA3145041A1 (fr) * 2019-07-29 2021-02-04 Matthias Rath Ascorbate dans la prevention de la calcification vasculaire induite par la statine
CN121606573A (zh) * 2026-02-03 2026-03-06 上海市东方医院（同济大学附属东方医院） 一种用于预防或者治疗心肌梗死后室性心律失常的药物组合物

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB742544A (en) 1952-02-23 1955-12-30 Kodak Ltd Enteric products
FR2833M (fr) 1962-06-12 1964-10-05 I N I C O Ind Nuclear Invest C
GB1142757A (en) 1967-01-26 1969-02-12 Carter Wallace Therapeutic compositions
IT987503B (it) 1969-03-24 1975-03-20 Monsanto Co Composizione a base di acido glu tarico con buone caratteristiche di igroscopicita e stabilita
BE759520A (fr) 1969-11-28 1971-04-30 Aspro Nicholas Ltd Compositions d'aspirine
US3887700A (en) 1969-11-28 1975-06-03 Aspro Nicholas Ltd Analgesic formulations
JPS58126879A (ja) 1982-01-25 1983-07-28 Nippon Chemiphar Co Ltd 光学活性なピペラジン誘導体ならびに心筋梗塞の予防および治療剤
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
AU5160590A (en) 1989-02-16 1990-09-05 Angio-Medical Corporation Composition and method for treatment of gastric and duodenal ulcers and mucosal erosions
GB9104854D0 (en) 1991-03-07 1991-04-17 Reckitt & Colmann Prod Ltd Sustained release compositions
JP3228347B2 (ja) 1991-06-25 2001-11-12 三菱化学株式会社 シクロプロペノン誘導体
DE69321087T2 (de) 1992-12-25 1999-05-20 Mitsubishi Chemical Corp., Tokio/Tokyo Alpha-aminoketon Derivate
US6316487B1 (en) * 1993-06-16 2001-11-13 Aryx Therapeutics Compounds for treatment of cardiac arrhythmia synthesis, and methods of use
AU5787996A (en) 1995-04-19 1996-11-07 Lipoprotein Technologies, Inc. Compositions, kits, and methods for administration of antilipemic and anti-platelet aggregation drugs
TWI238064B (en) 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
NZ336035A (en) 1996-11-05 2002-03-28 Childrens Medical Center Angiogenesis inhibitory composition comprising an inhibitory compound and antiinflammatory drug
US6245797B1 (en) 1997-10-22 2001-06-12 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardio-and-cerebrovascular disease
US6884792B2 (en) 1999-01-08 2005-04-26 Marvin B. Bacaner Bretylium compositions and kits and their use in preventing and treating cardiovascular conditions
IL144199A0 (en) 1999-01-08 2002-05-23 Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
FR2838057B1 (fr) 2002-04-05 2005-07-08 Servier Lab Nouvelle association d'un antithrombotique et d'aspirine
AU2003226148A1 (en) 2002-04-05 2003-10-27 Merck & Co., Inc. Method for inhibiting bone resorption with an alendronate and vitamin d formulation
AU2003227691B2 (en) 2002-05-03 2008-05-15 Hexal Ag Stable pharmaceutical formulation for a combination of a statin and an ace inhibitor
MXPA05000050A (es) 2002-07-03 2005-04-08 Esperion Therapeutics Inc Composiciones farmaceuticas y metodos para tratar, prevenir y manejar el colesterol, dislipidemia y enfermedades relacionadas.
US20050142129A1 (en) 2002-10-15 2005-06-30 Mangano Dennis T. Methods of preventing morbidity and mortality by perioperative administration of a blood clotting inhibitor
WO2005018635A2 (fr) 2003-08-07 2005-03-03 Cardiome Pharma Corp. Activite i modulant des canaux ioniques
PE20050438A1 (es) 2003-10-20 2005-06-14 Esperion Therapeutics Inc Formulas farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y la prevencion de sindromes coronarios agudos

Also Published As

Publication number Publication date
US20120178724A1 (en) 2012-07-12
US8183284B2 (en) 2012-05-22
EP1906966A2 (fr) 2008-04-09
AR055091A1 (es) 2007-08-08
BRPI0613670A2 (pt) 2011-01-25
JP4880685B2 (ja) 2012-02-22
MX2008001063A (es) 2008-03-19
SMAP200800012A (it) 2008-02-27
AU2006271230A1 (en) 2007-01-25
RU2376994C2 (ru) 2009-12-27
CN101227908A (zh) 2008-07-23
IL188831A0 (en) 2008-08-07
WO2007010498A3 (fr) 2007-05-31
NO20080890L (no) 2008-03-03
JP2009502773A (ja) 2009-01-29
KR20080017489A (ko) 2008-02-26
SMP200800012B (it) 2008-02-27
TW200744613A (en) 2007-12-16
PE20070369A1 (es) 2007-05-16
RU2007148908A (ru) 2009-08-27
ZA200800564B (en) 2008-12-31
US20070021395A1 (en) 2007-01-25
CA2615975C (fr) 2012-11-27
WO2007010498A2 (fr) 2007-01-25
CA2615975A1 (fr) 2007-01-25

Similar Documents

Publication Publication Date Title
MA29622B1 (fr) Compositions permettant de reduire l'incidence d'une arythmie d'origine medicamenteuse
CR10091A (es) Compuestos orgánicos
TNSN01130A1 (fr) Formulations a liberation prolongee pour des secretagogues d'hormone de croissance
MA29713B1 (fr) Derives de tetrahydroindolone et de tetrahydroindazolone
MA29744B1 (fr) Formulations posologiques solides de medicaments presentant une adsorption buccale amelioree
MA53126B1 (fr) Agents de dégradation sélectifs du récepteur des oestrogènes
MA33811B1 (fr) Composés et méthodes utilisés pour la modulation kinases et indications à cet effet
TNSN04111A1 (fr) Derives de quinazoline pour le traitement d'une croissance cellulaire anormale
MA27509A1 (fr) Formulations a liberation prolongee contenant de la lamotrigine
TNSN08313A1 (fr) Des formes pharmaceutiques resistantes a la modification
WO2003105800A3 (fr) Forme galenique, se presentant sous forme de film adherant a la muqueuse, pour l'administration de principes actifs du cannabis
MA29273B1 (fr) Combinaison synergique de xolair/omalizumab/e25 et d'un agent immunosuppresseur
ATE368031T1 (de) Neue gamma secretase inhibitoren
ATE556060T1 (de) Monocyclische anilidspirohydantoine als cgrp- rezeptorantagonisten
BRPI0410767A (pt) formulações farmacêuticas de partìcula pequena de agentes antiataque e antidemência e agentes imunossupressores
MA29528B1 (fr) Agents de fixation
EP1100522A4 (fr) Administration de substances actives par la voie pulmonaire
TR200402704T4 (tr) Yeni fenil-propargileter türevleri
DE60137337D1 (de) Vorbeugende und therapeutsche monoklonale antikörper gegen vacciniavirusantigene
BR0005765A (pt) Combinação de inibidores de aldose redutase e agentes anti-hipertensivos para o tratamento de complicações diabéticas
DE60206198D1 (de) Tetrahydrochinolinderivate als muscarinische agonisten
MA31796B1 (fr) Composes organiques
MA29723B1 (fr) Composes
BR0002953A (pt) Composições e tratamento para complicações diabéticas
MA29969B1 (fr) Formulations de quinolinones